Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Moderate Buy” by Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given an average rating of “Moderate Buy” by the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $81.60.

Several research firms recently commented on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $68.55 on Monday. The firm’s 50 day simple moving average is $68.02 and its 200 day simple moving average is $68.64. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics has a one year low of $51.06 and a one year high of $82.22. The company has a market cap of $8.13 billion, a PE ratio of 24.66, a P/E/G ratio of 0.28 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period last year, the company earned $1.11 EPS. The firm’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts anticipate that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the transaction, the director owned 43,669 shares in the company, valued at $2,891,324.49. This trade represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,250 shares of company stock worth $6,299,746 in the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. DLD Asset Management LP increased its stake in shares of Halozyme Therapeutics by 20.0% in the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after acquiring an additional 5,000,000 shares in the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $124,031,000. Voloridge Investment Management LLC bought a new stake in Halozyme Therapeutics during the 3rd quarter valued at $77,587,000. Finally, Qube Research & Technologies Ltd bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.